Sun and Ranbaxy marriage puts Sun founder Shanghvi in position to influence industry

Sun Pharma Managing Director Dilip Shanghvi

The combo of Sun Pharmaceutical and Ranbaxy Laboratories just weeks ago created a significant force in the global generics market by any number of measures. It is India's largest drugmaker by far and the largest Indian drugmaker selling into the U.S. market. It is the fifth-largest generic company globally with combined sales of $4.2 billion. While it is significantly smaller than leader Teva Pharmaceutical ($TEVA) with more than $20 billion in annual revenues, Sun is large enough to be a significant force. All of this bestows on Sun founder and managing director Dilip Shanghvi new influence in the global pharma industry. As such, he is included in this year's FierceBiotech's The 25 most influential people in biopharma in 2015. Check out the report and see who else is on the list with Shanghvi. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.